Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD.
Toyoda H, Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
Toyoda H, et al. Among authors: tomita e.
Gastro Hep Adv. 2023 Aug 2;2(8):1093-1102. doi: 10.1016/j.gastha.2023.07.018. eCollection 2023.
Gastro Hep Adv. 2023.
PMID: 39131553
Free PMC article.